DRD5 and obstructive sleep apnea syndrome: Our study found that DRD5 and TFAP2A expressions were upregulated in OSA patients after CPAP treatment, suggesting that CPAP may improve abnormal ROS levels and inhibited chronic intermittent hypoxia-caused ferroptosis caused by targeting elevating the expressions of DRD5 and TFAP2A.